vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 45.45 percent increase over losses of $(0.11) per share from the same period last year. The company reported $9.00 thousand in sales this quarter. This is the same as the same period last year.
Provention Bio Provides Update On Potential Timing Of Teplizumab At-Risk Type 1 Diabetes (T1D) Biologics License Application (BLA) Resubmission
Data collection completed for PROTECT Pharmacokinetic/Pharmacodynamic (PK/PD) substudy
Company working with the U.S. FDA to finalize the design of population PK model to be used to analyze substudy data and plans to
